cover
Contact Name
Zanastia Sukmayanti
Contact Email
zanassukma@gmail.com
Phone
+6289513739598
Journal Mail Official
inajemdperkeni@gmail.com
Editorial Address
Jl. Salemba 1, No. 22G, Kenari Senen DKI Jakarta – Indonesia
Location
Kota adm. jakarta selatan,
Dki jakarta
INDONESIA
Indonesian Journal of Endocrinology Metabolism and Diabetes (InaJEMD)
ISSN : 30483271     EISSN : 30631408     DOI : -
Core Subject : Health,
Indonesian Journal of Endocrinology Metabolism and Diabetes (InaJEMD) is an open accessed online journal and comprehensive peer-reviewed medical journal published by the Indonesian Society of Endocrinology since 2024. Our main mission is to publish and disseminate research results that are relevant to current and future scientific development needs. InaJEMD is an open accessed online journal. We are welcome authors for original articles, case report, case series, case illustration, review articles, systematic review, and clinical practice. Authors are invited to submit articles that have not been published previously and are not under consideration elsewhere. Preparations of manuscript should follow the author guidelines of InaJEMD.
Articles 51 Documents
Efficacy and Safety of Testosterone Treatment in Male Hypogonadism: a Systematic Review Ekvan Danang Setya Pramudito; Fergie Marie Joe Grizella Runtu; Amalia Dwi Mulyani; Ardy Wildan
‎ InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes Vol. 2 No. 2 (2025): InaJEMD Vol. 2, No. 2
Publisher : PP PERKENI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.66266/inajemd.v2i2.71

Abstract

Male hypogonadism may occur because of either congenital conditions or dysfunction that arises along the hypothalamic-pituitary-gonadal axis. As part of the lifelong management of male hypogonadism, testosterone replacement therapy (TRT) has been the most important therapy, although its effectiveness and safety are subject to controversy. This systematic review was undertaken to investigate the effectiveness and safety of TRT in men with hypogonadism. Searches were conducted in the literature through MEDLINE, CENTRAL, and ScienceDirect. The inclusion criteria were restricted to RCTs reported within five years. Out of 2,471 published articles, 16 were found eligible for analysis. Results showed that TRT is effective in raising serum testosterone levels in male with hypogonadism no matter the mode of administration, whether injected, oral or topical as in gels. In addition, TRT has improved body composition by decreasing fat and lean muscle mass. An increase in PSA commonly occurs in most patients, yet no research proves that TRT increases the development of prostate cancer and cardiovascular disease. Most commonly, the adverse effects are arrhythmias and increase in blood pressure, especially among those who undergo oral TRT. Amelioration of different symptoms such as erectile dysfunction, decreased libido, and fatigue in patients with hypogonadism was also achieved by TRT. Overall, it can be concluded that, TRT is generally safe and effective but requires close monitoring, but also one where monitoring should regularly be performed because of possible side effects, more research is needed.